Satigrel
Code | Size | Price |
---|
TAR-T24760-5mg | 5mg | £1,171.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24760-50mg | 50mg | £2,303.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24760-100mg | 100mg | £3,042.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Satigrel is a new antiplatelet agent. It also inhibits platelet accumulation in prosthetic arterial grafts.
CAS:
111753-73-2
Formula:
C20H19NO4
Molecular Weight:
337.375
Purity:
0.98
SMILES:
COc1ccc(cc1)C(=C(CCC(O)=O)C#N)c1ccc(OC)cc1
References
1. Moriwaki H, Matsumoto M, Handa N, Hashikawa K, Hori M, Nishimura T. Effect of E5510, a novel antiplatelet agent, on platelet deposition in atherothrombotic lesions: evaluation by 111In platelet scintigraphy. Nucl Med Commun. 2000 Nov;21(11):1051-8. PubMed PMID: 11192711.
2. Hoshi S, Goto M, Koyama N, Nomoto K, Tanaka H. Regulation of vascular smooth muscle cell proliferation by nuclear factor-kappaB and its inhibitor, I-kappaB. J Biol Chem. 2000 Jan 14;275(2):883-9. PubMed PMID: 10625622.
3. Sarker KP, Abeyama K, Nishi J, Nakata M, Tokioka T, Nakajima T, Kitajima I, Maruyama I. Inhibition of thrombin-induced neuronal cell death by recombinant thrombomodulin and E5510, a synthetic thrombin receptor signaling inhibitor. Thromb Haemost. 1999 Sep;82(3):1071-7. PubMed PMID: 10494766.
4. Bianchi ML, Ardissino GL, Schmitt CP, Dacc? V, Barletta L, Claris-Appiani A, Mehls O. No difference in intestinal strontium absorption after an oral or an intravenous 1,25(OH)2D3 bolus in normal subjects. For the European Study Group on Vitamin D in children with renal failure. J Bone Miner Res. 1999 Oct;14(10):1789-95. PubMed PMID: 10491227.